Altre lingue AstraZeneca PLC

Azioni

AZN

GB0009895292

Mercato chiuso - London S.E. Altri mercati azionari 17:35:17 31/05/2024			Variaz. 5gg	Var. 1 gen.
12.190 ^GBX	+1,35%		-0,86%	+15,00%

31/05	Fusion Pharmaceuticals ottiene l'ordine del tribunale che approva l'accordo con AstraZeneca	MT
30/05	ASTRAZENECA PLC : giudizio positivo da Goldman Sachs	ZM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal	31/05
ASTRAZENECA PLC : Goldman Sachs maintient sa recommandation à l'achat	30/05
ASTRAZENECA PLC : Goldman Sachs revoit son opinion à la hausse	30/05
Jefferies and UBS cut Anglo American	30/05
Dr Martens cuts payout as profit plummets	30/05
ASTRAZENECA : Is no more a Sell but a Buy opportunity for Goldman Sachs	30/05
AstraZeneca drug lowers cholesterol in phase 1 trial	29/05
Astrazeneca Says AZD0780 Demonstrated Significant LDL-C Reduction On Top Of Statin In Phase I Trial	29/05
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	28/05
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	28/05
AstraZeneca Says Potential Lung Cancer Treatment Improved Overall Survival Compared With Chemotherapy	28/05
ASTRAZENECA : JP Morgan reiterates its Buy rating	28/05
Astrazeneca Pharma India's Net Profit Rises in Fiscal Q4	28/05
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	27/05
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	27/05
Astra, Daiichi hail positive survival data for Dato-DXd	27/05
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial	27/05
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	23/05
ASTRAZENECA PLC : Stifel Nicolaus favorable sur le dossier	22/05
AstraZeneca PLC Furthers Ambition to Transform Outcomes in Early Lung Cancer and Redefine Metastatic Breast Cancer Treatment at ASCO 2024	22/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

ASTRAZENECA : Il forte Q1 fa sperare in un aggiornamento della guidance

25 aprile 2024 alle 18:02

'Un altro anno positivo' per AstraZeneca: CEO Pascal Soriot

09 febbraio 2023 alle 16:04